Biomea Fusion (BMEA) Competitors $1.87 +0.04 (+2.19%) As of 01:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMEA vs. CMPX, AQST, CRVS, IMAB, YMAB, ATXS, VIGL, NBTX, OLMA, and FULCShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Compass Therapeutics (CMPX), Aquestive Therapeutics (AQST), Corvus Pharmaceuticals (CRVS), I-Mab (IMAB), Y-mAbs Therapeutics (YMAB), Astria Therapeutics (ATXS), Vigil Neuroscience (VIGL), Nanobiotix (NBTX), Olema Pharmaceuticals (OLMA), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Biomea Fusion vs. Its Competitors Compass Therapeutics Aquestive Therapeutics Corvus Pharmaceuticals I-Mab Y-mAbs Therapeutics Astria Therapeutics Vigil Neuroscience Nanobiotix Olema Pharmaceuticals Fulcrum Therapeutics Compass Therapeutics (NASDAQ:CMPX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends. Do insiders & institutionals hold more shares of CMPX or BMEA? 68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 29.8% of Compass Therapeutics shares are owned by company insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate CMPX or BMEA? Compass Therapeutics presently has a consensus target price of $12.89, suggesting a potential upside of 328.91%. Biomea Fusion has a consensus target price of $16.80, suggesting a potential upside of 798.40%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Compass Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.17 Which has stronger valuation & earnings, CMPX or BMEA? Compass Therapeutics has higher revenue and earnings than Biomea Fusion. Compass Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K488.86-$49.38M-$0.45-6.68Biomea FusionN/AN/A-$138.43M-$3.03-0.62 Is CMPX or BMEA more profitable? Compass Therapeutics' return on equity of -53.11% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -53.11% -46.14% Biomea Fusion N/A -243.95%-140.74% Which has more volatility & risk, CMPX or BMEA? Compass Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Does the media prefer CMPX or BMEA? In the previous week, Compass Therapeutics and Compass Therapeutics both had 1 articles in the media. Biomea Fusion's average media sentiment score of 0.51 beat Compass Therapeutics' score of -0.31 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCompass Therapeutics beats Biomea Fusion on 8 of the 14 factors compared between the two stocks. Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.99M$3.07B$5.77B$9.77BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-0.6221.0430.3325.98Price / SalesN/A393.04469.88121.59Price / CashN/A43.2325.7828.79Price / Book1.329.769.496.05Net Income-$138.43M-$54.08M$3.27B$265.38M7 Day Performance7.47%3.34%2.53%3.02%1 Month Performance2.19%4.81%4.05%1.38%1 Year Performance-75.43%10.52%30.79%19.31% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion3.51 of 5 stars$1.87+2.2%$16.80+798.4%-76.0%$110.99MN/A-0.6250CMPXCompass Therapeutics2.7184 of 5 stars$2.87-3.4%$12.89+349.1%+139.7%$410.70M$850K-6.3820AQSTAquestive Therapeutics2.1295 of 5 stars$4.18+1.7%$10.14+142.7%-10.8%$409.86M$57.56M0.00160Positive NewsCRVSCorvus Pharmaceuticals2.4035 of 5 stars$5.32-2.0%$15.00+182.0%+29.1%$404.61MN/A-5.2730IMABI-Mab2.4883 of 5 stars$5.09+4.5%$6.00+17.9%+318.9%$397.69M$3.89M0.00380News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionGap UpYMABY-mAbs Therapeutics2.6829 of 5 stars$8.52flat$9.62+12.9%-37.9%$387.14M$87.68M0.00150ATXSAstria Therapeutics2.7451 of 5 stars$6.78-1.0%$29.00+327.7%-44.8%$386.58MN/A-3.3730VIGLVigil Neuroscience1.8193 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340NBTXNanobiotix0.7746 of 5 stars$8.80+11.3%$8.00-9.1%+91.1%$379.23M$39.18M0.00100Positive NewsGap DownOLMAOlema Pharmaceuticals1.9947 of 5 stars$5.76+4.5%$24.00+316.7%-51.8%$378.17MN/A0.0070FULCFulcrum Therapeutics0.9229 of 5 stars$6.64-2.6%$7.57+14.0%-25.0%$368.90M$80M0.00100 Related Companies and Tools Related Companies CMPX Alternatives AQST Alternatives CRVS Alternatives IMAB Alternatives YMAB Alternatives ATXS Alternatives VIGL Alternatives NBTX Alternatives OLMA Alternatives FULC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMEA) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access